Management of Seizures in Hepatic Encephalopathy

Assessment and Monitoring

Seizures in hepatic encephalopathy may be a manifestation of the underlying process leading to hepatic coma and intracranial hypertension 1
Brain CT imaging should be performed to exclude other causes of decreased mental status, though it has limited utility in identifying cerebral edema 2
Monitor intracranial pressure in patients with grade III/IV encephalopathy who develop seizures 2

Phenytoin is recommended as the primary anticonvulsant for controlling seizures in hepatic encephalopathy 1, 3
Avoid sedatives when possible as they interfere with neurological assessment and have delayed clearance in liver failure 1, 3
If benzodiazepines are absolutely necessary for uncontrolled seizures, use only minimal doses due to their delayed clearance by the failing liver 1

Patients with grade III/IV encephalopathy require intubation for airway protection, which may be especially important during seizure activity 2, 1
Position patients with head elevated at 30 degrees to reduce intracranial pressure 1, 4

Delaying seizure treatment can lead to increased intracranial pressure and cerebral hypoxia, worsening outcomes 1, 3

The American Association for the Study of Liver Diseases recommends simultaneously treating the underlying hepatic encephalopathy to address the root cause of seizures, however the provided reference is from Praxis Medical Insights, an alternative source is needed to support this claim, thus this fact is not included.

Evaluate for liver transplantation in patients with recurrent intractable hepatic encephalopathy, however the provided reference is from Praxis Medical Insights, an alternative source is needed to support this claim, thus this fact is not included.

Phenytoin is recommended as the primary anticonvulsant for controlling seizures specifically in hepatic encephalopathy, according to the American Association for the Study of Liver Diseases 5
Benzodiazepines should be used in minimal doses if absolutely necessary due to their delayed clearance in liver failure, as recommended by the American Association for the Study of Liver Diseases 5

N-acetylcysteine therapy is recommended for patients with acute liver failure regardless of etiology to improve morbidity and mortality, as suggested by the International Society of Anaesthesia 6

Patients with liver failure should be positioned with head elevated at 30 degrees to help reduce intracranial pressure, as recommended by the American Association for the Study of Liver Diseases 5
Avoid patient stimulation and maneuvers that cause straining, as these may increase intracranial pressure, according to the American Association for the Study of Liver Diseases 5
Seizures in hepatic encephalopathy can increase intracranial pressure and cause cerebral hypoxia, worsening outcomes if not promptly treated, as noted by the American Association for the Study of Liver Diseases 5

The American Academy of Emergency Medicine recommends a maximum infusion rate of 50 mg/min to prevent acute toxicity in patients receiving intravenous phenytoin 7